CL Increasing prevalence of overweight among US adults. JAMA.
1994;272205- 211Link to Article
et al. Long-term weight control study, I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther.
1992;51586- 594Link to Article
Not Available, Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations. MMWR Morb Mortal Wkly Rep. 1997;461061- 1066
Not Available, Statement of Stadel B. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting Condensed Transcript and Concordance. SAG Corp 1995;261- 268
CE Guidance for Treatment of Adult Obesity, Shape Up America! Bethesda, Md Wyeth-Ayerst Laboratories1996;
TI The genetics of obesity [review]. Metabolism.
1995;444- 6Link to Article
C A brief overview of human energy metabolism and its relationship to essential obesity. Am J Clin Nutr. 1992;55
RL Molecular genetics in clinical practice, XII: the genetics of obesity. Hosp Pract (Off Ed). March15 1998;55- 57
CS The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med.
1999;130671- 680Link to Article
RL Divergent trends in obesity and fat intake patterns: the American paradox. Am J Med.
1997;102259- 264Link to Article
SA Obesity in Britain: gluttony or sloth? BMJ.
1995;311437- 439Link to Article
WH Actual causes of death in the United States. JAMA.
1993;2702207- 2212Link to Article
et al. Body weight and mortality among women. N Engl J Med.
1995;333677- 85Link to Article
D Overweight, underweight, and mortality: a prospective study of 48287 men and women. Arch Intern Med.
1996;156958- 963Link to Article
F Medical hazards of obesity. Ann Intern Med.
655- 660Link to Article
A Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest.
1996;972601- 2610Link to Article
TB Elevated C-reactive protein levels in overweight and obese adults. JAMA.
1999;2822131- 2135Link to Article
JP Severe obesity: expensive to society, frustrating to treat, but important to confront. South Med J.
1995;88895- 902Link to Article
O Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med.
1999;130883- 890Link to Article
et al. Liver fibrosis in overweight patients. Gastroenterology.
2000;1181117- 1123Link to Article
D Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis.
1994;53565- 568Link to Article
et al. A prospective study of risk factors for pulmonary embolism in women. JAMA.
1997;277642- 645Link to Article
Not Available, Thrombolytic Therapy for Pulmonary Embolism: is it effective? is it safe? when is it indicated? Arch Intern Med.
1997;1572550- 2556Link to Article
NH Safety and effectiveness of a multidisciplinary very-low-calorie diet program for selected obese individuals. J Am Diet Assoc. 1991;911582- 1584
MJ Three-year follow-up of participants in a commercial weight loss program: can you keep it off? Arch Intern Med.
1996;1561302- 1306Link to Article
CP Long-term follow-up of patients attending a combination very-low calorie diet and behavior therapy weight loss programme. Int J Obes Relat Metab Disord. 1992;16605- 613
MF Thirty-month evaluation of a popular very-low-calorie diet program. Arch Fam Med.
1993;21042- 1048Link to Article
DL A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up source. Int J Eat Disord.
1997;22203- 212Link to Article
GD Treatment of obesity by very-low-calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes Relat Metab Disord. 1989;13
WJ Minireview: anorectic agents lower a body weight set point. Life Sci.
1982;302043- 2055Link to Article
MA The pharmacologic approach to the treamtent of obesity. J Clin Pharmacol.
1997;37453- 473Link to Article
T The long-term management of obesity in general practice. Br J Clin Pract. 1965;19395- 398
EC The use of diethylpropion in the treatment of obesity. Br J Clin Pract. 1964;18210- 211
RH Long-term use of diethylpropion in obesity. Curr Med Res Opin.
1973;1489- 493Link to Article
AM Diethylpropion in the treatment of "refractory" obesity. BMJ. April8 1961;1009- 1111
RJ Mazindol in obesity with known cardiac disease: a clinical evaluation. J Int Med Res. 1974;2347- 349
G Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. J Int Med Res. 1976;4305- 319
S Clinical studies with mazindol. Obes Res.
549S- 552SLink to Article
LJ Comparison of continuous and intermittent anorectic therapy in obesity. BMJ.
1968;1352- 354Link to Article
JA Long-term weight loss with sibutramine [abstract]. Int J Obes Relat Metab Disord. 1995;19
LR Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994;18129- 135
DH A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med.
1984;1441143- 1148Link to Article
S Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res. 1972;14726- 738
J A comparative trial of different regimens of phentermine and fenfluramine in obesity. Practitioner. 1973;211232- 234
DJ Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol.
1997;1211613- 1618Link to Article
et al. Sibutramine—dose response and long-term efficacy in weight loss, a double-blind study. Int J Obes Relat Metab Disord. 1994;1860
E Long-term maintenance of weight loss after a very-low-calorie diet: a ramdomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med.
1999;106179- 184Link to Article
ME Sibutramine—a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997;21
D Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992;55
et al. orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995;19221- 226
et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care.
1998;211288- 1294Link to Article
et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet.
1998;352167- 173Link to Article
et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA.
1999;281235- 242Link to Article
B Adiposity as a risk determinant for postmenopausal breast cancer. Int J Obes Relat Metab Disord.
2000;24527- 533Link to Article
et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol.
1996;361006- 1011Link to Article
Food and Drug Administration, Center for Drug Evaluation and Research, DA 20-766.Xenical (Orlistat). Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting 669 March 1998 Gaithersburg, Md.
et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obes Relat Metab Disord. 1989;13635- 645
et al. Efficacy and safety of long-term fluoxetine treatment of obesity–maximizing success. Obes Res.
481S- 490SLink to Article
W A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147876- 881
et al. Fluoxetine has potential in obese NIDDM—multi-center Canadian Trial. Diabetes. 1989;38
JK Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetes Med.
1994;11105- 110Link to Article
et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet:a controlled clinical trial. Obes Res.
1995;3549- 557Link to Article
EK Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. Am J Physiol. 1999;276L213- L219
AO Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci.
1997;1821- 25Link to Article
DR Dexfenfluramine: an updated review of its therapeutic use in the management of obesity. Drugs.
1996;52696- 724Link to Article
D The anorectic and hypotensive effect of fenfluramine in obesity. J R Coll Gen Pract. 1977;27497- 501
P International trial of long-term dexfenfluramine in obesity. Lancet.
1989;21142- 1145Link to Article
K Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. J Intern Med.
1992;232119- 127Link to Article
et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med.
1997;337581- 588Link to Article
JM Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: the CARDIA study [abstract]. Circulation.
282Link to Article
HB Low prevalence of vavular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol.
1999;341159- 1162Link to Article
DJ Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol.
1999;841335- 1338Link to Article
FA Diet drug-related cardiac valve disease: The Mayo Clinic Echocardiographic Laboratory experience. Mayo Clin Proc.
2000;75456- 461Link to Article
M Asymptomatic mitral and aortic valve disease is seen in half of patients taking "Phen-Fen" [letter]. Arch Intern Med.
1998;158102Link to Article
CL Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA.
2000;2831703- 1709Link to Article
T Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation.
2000;1012071- 2077Link to Article
SB Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation.
1999;1002161- 2167Link to Article
et al. The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res.
1998;6278- 284Link to Article
JT An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med.
1998;339725- 732Link to Article
et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med.
1998;339713- 718Link to Article
et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med.
1998;129870- 874Link to Article
et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res.
1999;7313- 322Link to Article
LE A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med.
1998;339719- 724Link to Article
MD Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc.
1999;741191- 1197Link to Article
AJ Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment [letter]. N Engl J Med.
1998;339771Link to Article
W Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996;5235- 237
et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;5775- 81
M The "Phen-Pro" diet drug combination is not associated with valvular heart disease. Arch Intern Med.
1998;1581278- 1279Link to Article
et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res.
1999;7363- 369Link to Article
A The effects of anorectic agents on the pulmonary pressure and morphology of rat lungs after chronic administration. Arzneimittelforschung. 1972;222096- 2099
V Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation.
1996;942216- 2220Link to Article
D Phentermine resinate and the pulmonary vasculature of the rat. Arzneimittelforschung. 1977;272112- 2113
W A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmcol Res.
1990;22371- 378Link to Article
et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med.
1996;335609- 616Link to Article
G Effect of degree of weight loss on health benefits. Obes Res.
211S- 216SLink to Article
DJ Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16397- 415
I The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord. 1997;21
G What is a reasonable weight loss? patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol.
1997;6579- 85Link to Article
T The Learn Program for Weight Control. Dallas, Tex American Health Publishing Co1998;6- 18
et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA.
1996;276205- 210Link to Article
WP Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;491115- 1123
DL The role of exercise in weight regulation in nonathletes. Sports Med.
1991;11331- 349Link to Article
P Energy expenditure with indoor exercise machines. JAMA.
1996;2751424- 1427Link to Article
R How much physical activity is needed to minimize weight gain in previously obese women? Am J Clin Nutr. 1997;66551- 556
G Similar weight loss with low- or high-carbohydrate diets. Am J Clin Nutr. 1996;63823- 825
PM Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes. Diabetes Care.
1999;22889- 895Link to Article
A Weight loss with high and low carbohydrate 1200-kcal diets in free living women. Eur J Clin Nutr.
1997;51243- 248Link to Article
et al. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med.
1998;60338- 346Link to Article
ML Safe and effective management of the obese patient. Mayo Clinic Proc.
1999;741255- 1259Link to Article
R Late results of gastric bypass surgery for morbid obesity. J Am Coll Clin Nutr.
1994;13326- 331Link to Article
et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg.
1998;227637- 644Link to Article
et al. Who would have thought it? an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg.
1995;222339- 350Link to Article
et al. Effect of coronary artery bypass surgery on survival: results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet.
1994;344563- 570Link to Article